Evidence map›Paper›PMID 33331426›Full record

ArticleArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2020

IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER.

Renato Morato Zanatto, Gianni Santos, Júnea Caris Oliveira, Eduardo Marcucci Pracucho, Adauto José Ferreira Nunes, Gaspar Jesus Lopes-Filho, Sarhan Sydney Saad

Open access · diamondAbstract read
In one paragraph

Article in Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. CARNOY'S SOLUTION INCREASES LYMPH NODES COUNT IN COLON CANCER SPECIMENS WHEN COMPARED TO FORMALIN FIXATION: A RANDOMIZED TRIAL.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2022
    Trial
  2. Article
  3. Association between KRAS gene mutation and clinicopathological factors in patients with metastatic colorectal cancer.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Renato Morato ZanattoDepartment of Abdominal and Pelvic Surgery, Hospital Amaral Carvalho, Jaú, SP, Brazil.ORCID http://orcid.org/0000-0002-7791-6645
Gianni SantosDepartment of Biostatistics, Federal University of São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-5122-3536
Júnea Caris OliveiraDepartment of Abdominal and Pelvic Surgery, Hospital Amaral Carvalho, Jaú, SP, Brazil.ORCID http://orcid.org/0000-0002-6858-3690
Eduardo Marcucci PracuchoDepartment of Abdominal and Pelvic Surgery, Hospital Amaral Carvalho, Jaú, SP, Brazil.ORCID http://orcid.org/0000-0002-5195-7596
Adauto José Ferreira NunesPathology Department, Hospital Amaral Carvalho, Jaú, SP, Brazil.ORCID http://orcid.org/0000-0003-3473-9252
Gaspar Jesus Lopes-FilhoDepartment of Digestive Surgery, Federal University of São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-9344-6479
Sarhan Sydney SaadDepartment of Digestive Surgery, Federal University of São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-0395-6799
Hospital Amaral Carvalho · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKRAS mutations are important events in colorectal carcinogenesis, as well as negative predictors of response to EGFR inhibitors treatment.

aimTo investigate the association of clinical-pathological features with KRAS mutations in colorectal cancer patients treated.

methodsData from 69 patients with colorectal cancer either metastatic at diagnosis or later, were retrospectively analyzed. The direct sequencing and pyrosequencing techniques were related to KRAS exon 2. The mutation diagnosis and its type were determined.

resultsKRAS mutation was identified in 43.4% of patients. The most common was c.35G>T (p.G12V), c.35G>A (p.G12D) and c.38G>A (p.G13D). No correlation was found between KRAS mutation and age (p=0.646) or gender (p=0.815). However, mutated group had higher CEA levels at admission (p=0.048) and codon 13 mutation was associated with involvement of more than one metastatic site in disease progression (p=0.029). Although there was no association between primary tumor site and mutation diagnosis (p=0.568), primary colon was associated with worse overall survival (p=0.009).

conclusionThe KRAS mutation was identified in almost half of patients. Mutated KRAS group had higher levels of CEA at admission and the mutation at codon 13 was associated with involvement of more than one metastatic site in the course of the disease. Colon disease was associated with the worst overall survival.

Indexed as

Proto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overColorectal NeoplasmsFemaleHumansMaleMiddle AgedMutationProto-Oncogene Proteinsras ProteinsRetrospective StudiesKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID33331426
PMCPMC7743328
OpenAlexW3117789920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.